Frozen card revision. This is the recorded reading, not an automatically refreshed view. Current card ↗
R&D Allocation · TOPIC v1
Can comparing skin and lung fibrosis provide evidence for deciding which diseases to pursue with a drug?
Read article → Looking across diseases for drugs that treat fibrosis
2026-10-19 13:37:13.574 UTC · Last recorded update
Recorded editorial state, not a maturity score
Record a research plan to use shared fibrotic processes and organ differences in indication selection.
Permanent link to this revision ↗Can comparing skin and lung fibrosis provide evidence for deciding which diseases to pursue with a drug?
Patient-derived fibroblasts / three-dimensional skin and lung models / compound screening / multiomics
Comparing disease models during discovery, rather than considering other indications only after finding a candidate, may reveal shared response conditions and organ-specific ones.
This is a research plan, not demonstrated efficacy or indication expansion. Whether model responses correspond to clinical effects requires separate assessment.
Candidates with shared responses across skin and lung models, conditions that separate responses, reproducibility across donor samples and subsequent development decisions.
What would change our view: Reconsider use in indication decisions if between-model responses do not reproduce or are explained by culture variability rather than disease or organ differences.
A prospective test proposal, not a prediction score. A graph connection does not validate this hypothesis.
Mentioned in this issue
Mentioned in this issue
Mentioned in this issue
The human-derived fibrosis model plan and mouse placental experiment are distinct studies. They are connected through the question of surrounding conditions as well as cell-intrinsic differences, not evidence about each other’s pathology or drug effects.
Transplanted neural tissue and cultured fibrosis models have different uses. The comparison concerns evaluating the environment and function of interest, not cellular origin alone.
The physiological biomarker study of antidepressants and fibrosis models differ in disease and measurement method. They share the question of what must be established before a measurable difference can guide treatment selection.
Record a research plan to use shared fibrotic processes and organ differences in indication selection.
Reading at the time: 3D-MOFIB plans to begin with scleroderma and pulmonary fibrosis associated with Hermansky–Pudlak syndrome, screening compounds and molecular activity in patient-derived models to explore shared fibrosis mechanisms and organ-specific differences.
Earlier entries will appear here once more than five reader-facing revisions have accumulated.
3D-MOFIB: human-based models for fibrotic diseases ↗
NIH / NCATS · 2026-10-13 · research-program-description